Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

4/29/25 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MNPR alert in real time by email

WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver ("EASL") International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.

Late-breaker provides an opportunity to present "the most recent and significant findings," according to EASL. Criteria for late-breaker abstracts include: (1) they present the latest, up-to-date research findings; (2) the research is considered highly significant with the potential to impact the field in a substantial manner; and (3) clinical studies should be prospective. Late-breaker abstracts undergo a rigorous review, and the acceptance rate is lower than regular abstracts with only the most compelling abstracts selected.

Details of the EASL Congress 2025 late-breaker poster presentation are as follows:

Title: Sustained long-term clinical improvement in Wilson disease patients on tiomolybdate choline

Abstract Number: LB25251

Session: Late-breaker Posters

Date and Time: Wednesday, May 7, 8:30 a.m. CET

Presenter: Karl Heinz Weiss, M.D.

Location: Amsterdam, Netherlands

The poster to be presented at EASL 2025 will be available online at www.monopartx.com on May 7, 2025.

About Monopar Therapeutics Inc.

Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.

Investor Relations

Quan Vu

Chief Financial Officer

[email protected]

Follow Monopar on social media for updates:

X: @MonoparTx LinkedIn: Monopar Therapeutics

Get the next $MNPR alert in real time by email

Date

Price Target

Rating

Analyst

3/19/2025

$76.00

Overweight

Piper Sandler

1/10/2025

$72.00

Overweight

Piper Sandler

10/11/2024

$50.00

Buy

Rodman & Renshaw

11/1/2021

$9.00

Buy

HC Wainwright & Co.

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Chat with this insight

Recent Analyst Ratings for
$MNPR

$MNPR
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

$MNPR
Press Releases

Fastest customizable press release news feed in the world

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

$MNPR
SEC Filings

SEC Form DEFA14A filed by Monopar Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

SEC Form 10-Q filed by Monopar Therapeutics Inc.

$MNPR
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

Chief Operating Officer Cittadine Andrew covered exercise/tax liability with 744 shares and converted options into 1,791 shares, increasing direct ownership by 3% to 41,985 units (SEC Form 4)

Chief Executive Officer Robinson Chandler converted options into 4,106 shares and covered exercise/tax liability with 1,204 shares, increasing direct ownership by 5% to 65,993 units (SEC Form 4)

Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025

Chat with this insight

Recent Analyst Ratings for $MNPR

$MNPR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Financial Officer Radhakrishnan Karthik bought $25,188 worth of shares (1,550 units at $16.25) (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $25,574 worth of shares (32,508 units at $0.79), increasing direct ownership by 21% to 186,132 units (SEC Form 4)

Chief Operating Officer Cittadine Andrew bought $32,894 worth of shares (36,000 units at $0.91), increasing direct ownership by 31% to 153,624 units (SEC Form 4)

$MNPR Press Releases

Fastest customizable press release news feed in the world

Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers

Monopar Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments

$MNPR SEC Filings

SEC Form DEFA14A filed by Monopar Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.

SEC Form 10-Q filed by Monopar Therapeutics Inc.

$MNPR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Tactic Pharma Llc sold $1,166,690 worth of shares (33,334 units at $35.00) (SEC Form 4)

Chief Operating Officer Cittadine Andrew covered exercise/tax liability with 744 shares and converted options into 1,791 shares, increasing direct ownership by 3% to 41,985 units (SEC Form 4)

Chief Executive Officer Robinson Chandler converted options into 4,106 shares and covered exercise/tax liability with 1,204 shares, increasing direct ownership by 5% to 65,993 units (SEC Form 4)

Recent Analyst Ratings for
$MNPR

$MNPR
Insider Purchases

$MNPR
Press Releases

$MNPR
SEC Filings

$MNPR
Insider Trading